Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 15, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

August 15, 2018

Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
DRUG

Trehalose

90 mg/ml trehalose solution for IV infusion

Trial Locations (3)

G7H 7K9

Ecogene-21, Chicoutimi

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

G1J 1Z4

CHU de Québec-Université Laval- Hôpital Enfant-Jésus, Québec

Sponsors
All Listed Sponsors
lead

Bioblast Pharma Ltd.

INDUSTRY

NCT04226924 - Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose | Biotech Hunter | Biotech Hunter